1-{5-Chloro-1-[3-(trifluoromethyl)phenyl]-1H-indol-2-yl}-3-cyclopropylpropan-1-one | 934615-64-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-{5-Chloro-1-[3-(trifluoromethyl)phenyl]-1H-indol-2-yl}-3-cyclopropylpropan-1-one
• 英文别名: 1-[5-Chloro-1-[3-(trifluoromethyl)phenyl]indol-2-yl]-3-cyclopropylpropan-1-one
• CAS: 934615-64-2
• 化学式: C₂₁H₁₇ClF₃NO
• 分子量: 391.82
• InChiKey: WGNFBAMHPIQPNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Ethyl 5-chloro-1-[3-(trifluoromethyl)phenyl]-1H-indole-2-carboxylate 在 sodium hydride 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-{5-Chloro-1-[3-(trifluoromethyl)phenyl]-1H-indol-2-yl}-3-cyclopropylpropan-1-one
  参考文献：
  名称：

  Discovery of N-Aryl-2-acylindole human glucagon receptor antagonists

  摘要：

  A novel class of N-aryl-2-acylindole human glucagon receptor (hGCGR) antagonists is reported. These compounds demonstrate good pharmacokinetic profiles in multiple preclinical species. One compound from this series, indole 33, is orally active in a transgenic murine pharmacodynamic model. Furthermore, a 1 mg/kg oral dose of indole 33 lowers ambient glucose levels in an ob/ob/hGCGR transgenic murine diabetes model. This compound was deemed suitable for preclinical safety studies and was found to be well tolerated in an 8-day experimental rodent tolerability study. The combination of preclinical efficacy and safety observed with compound 33 highlights the potential of this class as a treatment for type 2 diabetes. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.105

文献信息

• Acyl indoles, compositions containing such compounds and methods of use
  申请人：Kim M. Ronald

  公开号：US20070088071A1

  公开（公告）日：2007-04-19

  The present invention relates to substituted indoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus and related conditions.

  本发明涉及替代吲哚类化合物，含有这种化合物的组合物，以及治疗方法。这些化合物是胰高血糖素受体拮抗剂，因此可用于治疗、预防或延缓2型糖尿病及相关疾病的发生。
• US7598398B2
  申请人：——

  公开号：US7598398B2

  公开（公告）日：2009-10-06